Preprint · OA
via OpenAlex
Mild cognitive impairment due to Alzheimer disease in the community
Ronald Carl Petersen, Paul S. S Aisen, Bradley F. Boeve, Yonas E. Geda, Robert J. Ivnik, David S. Knopman, Michelle M. Mielke, V. Shane Pankratz, Rosebud O. Roberts, Walter A. Rocca, Stephen D. Weigand, Michael Walter Weiner, Heather J. Wiste, Clifford R. Jack
Annals of Neurology · 2013 · ▲ 265 citations
Abstract
OBJECTIVE: The newly proposed National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) due to Alzheimer disease (AD) suggest a combination of clinical features and biomarker measures, but their performance in the community is not known. METHODS: The Mayo Clinic Study of Aging (MCSA) is a population-based longitudinal study of nondemented subjects in Olmsted County, Minnesota. A sample of 154 MCI subjects from the MCSA was compared to a sample of 58 amnestic MCI subjects from the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI-1) to assess the applicability of the criteria in both settings and to assess their outcomes. RESULTS: Fourteen percent of MCSA and 16% of ADNI-1 of subjects were biomarker negative. In addition, 14% of MCSA and 12% of ADNI-1 subjects had evidence for amyloid deposition only, whereas 43% of MCSA and 55% of ADNI-1 subjects had evidence for amyloid deposition plus neurodegeneration (magnetic resonance imaging atrophy, fluorodeoxyglucose positron emission tomography hypometabolism, or both). However, a considerable number of subjects had biomarkers inconsistent with the proposed AD model; for example, 29% of MCSA subjects and 17% of ADNI-1 subjects had evidence for neurodegeneration without amyloid deposition. These subjects may not be on an AD pathway. Neurodegeneration appears to be a key factor in predicting progression relative to amyloid deposition alone. INTERPRETATION: The NIA-AA criteria apply to most MCI subjects in both the community and clinical trials settings; however, a sizeable proportion of subjects had conflicting biomarkers, which may be very important and need to be explored.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/ana.23931
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Petersen, R.C., Aisen, P.S.S., Boeve, B.F., Geda, Y.E., Ivnik, R.J., Knopman, D.S., Mielke, M.M., Pankratz, V.S., Roberts, R.O., Rocca, W.A., Weigand, S.D., Weiner, M.W., Wiste, H.J., & Jack, C.R. (2013). Mild cognitive impairment due to Alzheimer disease in the community. <em>Annals of Neurology</em>. https://doi.org/10.1002/ana.23931
Vancouver
Petersen RC, Aisen PSS, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology. 2013. doi:10.1002/ana.23931.
BibTeX
@unpublished{ronald2013Mildco,
title = {Mild cognitive impairment due to Alzheimer disease in the community},
author = {Ronald Carl Petersen and Paul S. S Aisen and Bradley F. Boeve and Yonas E. Geda and Robert J. Ivnik and David S. Knopman and Michelle M. Mielke and V. Shane Pankratz and Rosebud O. Roberts and Walter A. Rocca and Stephen D. Weigand and Michael Walter Weiner and Heather J. Wiste and Clifford R. Jack},
journal = {Annals of Neurology},
year = {2013},
doi = {10.1002/ana.23931},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Dementia & Neuropsychologia 2016
Open access · CC-BY
Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?
Alzheimer s & Dementia 2024
Open access · CC-BY
Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
Brain 2009
Open access · CC-BY
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2020
Open access · CC-BY
Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
Alzheimer s & Dementia 2011
Citation only
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Annals of Neurology 2022
Open access · CC-BY